Clinical Trial Update: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on using umbilical cord-derived mesenchymal stromal cells for SARS-CoV-2-related ARDS, completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• Umbilical cord-derived mesenchymal stromal cells (umbilical cord-derived mesenchymal stromal cells)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Distress Syndrome | Phase 1, Phase 2 | Status: COMPLETED